Abaxis (Nasdaq: ABAX ) is expected to report Q3 earnings around Jan. 24. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Abaxis's revenues will grow 21.4% and EPS will grow 53.8%.
The average estimate for revenue is $46.0 million. On the bottom line, the average EPS estimate is $0.20.
Last quarter, Abaxis recorded revenue of $44.3 million. GAAP reported sales were 11% higher than the prior-year quarter's $40.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.18. GAAP EPS of $0.58 for Q2 were 287% higher than the prior-year quarter's $0.15 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 52.2%, 280 basis points worse than the prior-year quarter. Operating margin was 7.7%, 520 basis points worse than the prior-year quarter. Net margin was 29.2%, 2,090 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $182.6 million. The average EPS estimate is $0.77.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 162 members out of 178 rating the stock outperform, and 16 members rating it underperform. Among 43 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 41 give Abaxis a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Abaxis is outperform, with an average price target of $40.93.
Is Abaxis the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.